Equities research analysts expect Endologix, Inc. (NASDAQ:ELGX) to announce earnings of ($0.22) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Endologix’s earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.17). Endologix also reported earnings of ($0.22) per share during the same quarter last year. The business is expected to issue its next quarterly earnings results after the market closes on Wednesday, February 21st.
On average, analysts expect that Endologix will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.66) to ($0.56). For the next year, analysts expect that the company will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.53) to ($0.46). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Endologix.
Several equities analysts recently commented on the company. BidaskClub upgraded Endologix from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research cut Endologix from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Stifel Nicolaus reduced their target price on Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research report on Wednesday, November 8th. Canaccord Genuity reaffirmed a “hold” rating and set a $5.00 price target on shares of Endologix in a research note on Wednesday, November 8th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. Endologix presently has a consensus rating of “Hold” and an average target price of $5.41.
Endologix (NASDAQ ELGX) traded down $0.17 during trading on Wednesday, reaching $4.04. The company had a trading volume of 472,500 shares, compared to its average volume of 655,873. Endologix has a twelve month low of $3.89 and a twelve month high of $7.66. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90. The stock has a market capitalization of $351.34, a PE ratio of -4.34 and a beta of 0.42.
ILLEGAL ACTIVITY NOTICE: “-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/0-22-eps-expected-for-endologix-inc-elgx-this-quarter.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.